Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone

Obstetrics and Gynecology

Volumn 73, Issue 4, 1989, Pages 606-612

  Hargrove, Joel T ^a,b   Maxson, Wayne S ^a,b   Wentz, Anne Colston ^a,b   Burnett, Lonnie S ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Northwestern Center for Infertility and Reproductive Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

CLINICAL ARTICLE; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

CHOLESTEROL; CLIMACTERIC; COMPARATIVE STUDY; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ESTRADIOL; ESTROGENS, CONJUGATED; FEMALE; HUMAN; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGE; PILOT PROJECTS; PROGESTERONE;

EID: 0024594442     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Judd HL, Cleary RE, Creasman WT, et al. Estrogen replacement therapy. Obstet Gynecol 1981;58:267–75.
2. Hammond CB, Maxson WS. Current status of estrogen therapy for the menopause. Fertil Steril 1982;37:5–25.
3. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181–6.
4. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312–7.
5. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293:1164–7.
6. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293: 1167–70.
7. Whitehead M, Lane G, Siddle N, Townsend P, King R. Avoidance of endometrial hyperstimulation in estrogen-treated postmenopausal women. Semin Reprod Endocrinol 1983;1:41–53.
8. Gambrell RD Jr, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: Review. Am J Obstet Gynecol 1983;146:696–707.
9. Gambrell RD Jr, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA, Wright JM. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732–8.
10. Holst J, Cajander S, von Schoultz B. Endometrial effects of a continuous percutaneous oestrogen/low dose progestogen regimen for climacteric complaints. Maturitas 1987;9:63–7.
11. Lind T, Cameron EC, Hunter WM, et al. A prospective, controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol 1979;86(suppl):1–29.
12. Magos AL, Brincat M, Studd JWW, Wardle P, Schlesinger P, O’Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65:496–9.
13. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3:145–56.
14. Mattsson LA, Cullberg G, Samsioe G. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 1982;4:95–102.
15. Mattsson LA, Cullberg G, Samsioe G. A continuous estrogen-progestogen regimen for climacteric complaints. Effects on lipid and lipoprotein metabolism. Acta Obstet Gynecol Scand 1984;63: 673–7.
16. Hellberg D, Nilsson S. Pilot study to evaluate a new regimen to treat climacteric complaints with cyclic combined oestradiol valerate/medroxyprogesterone acetate. Maturitas 1987;9:103–7.
17. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1987;69:929–32.
18. Prough SG, Aksel S, Wiebe RH, Shepherd J. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987;157:1449–53.
19. Luciano AA, Turksoy RN, Carleo J, Hendrix JW. Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy. Obstet Gynecol 1988;71:39–43.
20. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511–8.
21. Gorrill MJ, Marshall JR. Pharmacology of estrogens and estrogen-induced effects on nonreproductive organs and systems. J Reprod Med Suppl 1986;31:842–47.
22. Ottosson UB. Oral progesterone and estrogen/progestogen therapy. Effects of natural and synthetic hormones on subfractions of HDL cholesterol and liver proteins. Acta Obstet Gynecol Scand 1984;127(suppl):1–37.
23. Fahraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest 1983;13:447–53.
24. Fahraeus L. Metabolic consequences of postmenopausal estrogen and progestogen treatment. Acta Obstet Gynecol Scand [Suppl] 1985;132:19–21.
25. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560–3.
26. Larsson-Cohn U, Fahraeus L, Wallentin L, Goran Z. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril 1981;35:172–9.
27. Nichols KC, Schenkel L, Benson H. 17 beta-estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Surv 1984;39:230–45.
28. Jensen J, Riis BJ, Strøm V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987;156:66–71.
29. Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy. A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151:746–50.
30. Whitehead MI, Townsend PT, Gill DK, Collins WP, Campbell S. Absorption and metabolism of oral progesterone. Br Med J [Clin Res] 1980;280:825–7.
31. Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985;44:622–6.
32. American College of Obstetricians and Gynecologists. Technical bulletin: Estrogen replacement therapy. Washington, DC: American College of Obstetricians and Gynecologists, no. 93, April, 1986:1–6.
33. Judd H, Utian WH. Introduction: What we hope to learn. Am J Obstet Gynecol 1987;156:1279–80.